Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Jet Injection for Influenza (JIFI)

29 september 2017 uppdaterad av: PharmaJet, Inc.

Jet Injection for Influenza: A Randomized Controlled Clinical Trial to Demonstrate Non Inferiority of Jet Injection vs. Needle and Syringe for Administration of Trivalent Inactivated Influenza Vaccine

The purpose of this study is to determine if the administration of a seasonal flu vaccine using a PharmaJet's needle-free injection device (STRATIS) is equivalent to needle and syringe administration, as measured by laboratory tests of immune response.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

1250

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Colorado
      • Fort Collins, Colorado, Förenta staterna, 80524
        • Poudre Valley Hospital
      • Fort Collins, Colorado, Förenta staterna, 80528
        • University of Colorado Health Harmony Campus
      • Loveland, Colorado, Förenta staterna, 80538
        • Medical Center of the Rockies

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 64 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Adults aged ≥18 and ≤64 years of age at the time of enrollment
  • Willing and able to give informed consent after reading the consent form and adequate opportunity to discuss the study with the investigator or qualified designee
  • Willing and able to adhere to all protocol required study procedures and to attend scheduled visits.
  • Able to receive the TIV influenza vaccine, based on University of Colorado Health (UCH) employee health flu screening guidelines.
  • Stable health status with no exclusionary medical or neuropsychiatric conditions as determined during the screening evaluation and based on the clinical judgment of the investigator or qualified designee.
  • Access to a consistent means of telephone contact

Exclusion Criteria:

  • Presence of any febrile illness (oral temperature >38°C) on the day of immunization. Such subjects will be reevaluated for enrollment after resolution of illness.
  • Presence of significant acute or chronic uncontrolled medical or neuropsychiatric illness and /or presence of any significant condition that may prohibit inclusion as determined by the investigator or his qualified designee. Uncontrolled is defined as: requiring institution of a new treatment within 1 month prior to study enrollment or change in medication dosage in the month prior to study enrollment.
  • Any immunosuppressive condition including: history of HIV infection, cancer or cancer treatment within 3 years of study enrollment, systemic glucocorticoids (in a dose ≥10 mg prednisone daily or equivalent for more than 7 consecutive days or for 10 or more days in total) within 1 month of study enrollment, or any other cytotoxic or immunosuppressive drug within 3 months of study enrollment. Any significant disorder of coagulation that would increase the risk of intramuscular injections or treatment with Coumadin derivatives or heparin.
  • Known or suspected to be allergic to eggs, chicken protein, gentamicin or influenza vaccine.
  • History of severe or previous serious adverse reaction after an influenza vaccination.
  • Receipt of any immunoglobulin and/or blood products within 3 months of immunization or planned administration of any of these products during the study period.
  • Prior history of any demyelinating disease including Guillain-Barre syndrome.
  • Presence of an active neurological disorder.
  • History of significant alcohol or drug abuse within one year prior to study enrollment.
  • Influenza vaccination or laboratory confirmed influenza infection within the previous six months before study vaccination or planned influenza vaccination during the study period.
  • Planned administration of any non-influenza vaccines 30 days prior to the study or during the study period.
  • Pregnant or plans to become pregnant during the study period.
  • Currently enrolled in another vaccine or drug study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: STRATIS Needle-Free
Patients assigned to this arm will receive AFLURIA vaccine administered using the Stratis needle-free injection device.
Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Andra namn:
  • trivalent inaktiverat influensavaccin (TIV)
  • influenza virus vaccine
Aktiv komparator: Needle-Syringe
Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Andra namn:
  • trivalent inaktiverat influensavaccin (TIV)
  • influenza virus vaccine

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Anti Influenza Type A/H1N1 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)
Tidsram: 28 days
The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for A/H1N1 antigen will not exceed 1.5 fold.
28 days
Anti Influenza Type A/H2N3 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)
Tidsram: 28 days
The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for each antigen to not exceed 1.5 fold.
28 days
Anti Influenza Type B Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)
Tidsram: 28 days
The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for each antigen to not exceed 1.5 fold.
28 days
Anti Influenza Type A/H1N1 Seroconversion
Tidsram: 28 days
Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of ≥1:40.
28 days
Anti Influenza Type A/H3N2 Seroconversion
Tidsram: 28 days
Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of ≥1:40.
28 days
Anti Influenza Type B Seroconversion
Tidsram: 28 days
Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of ≥1:40.
28 days

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of Subjects With Complaints Within 30 Minutes Following Vaccination
Tidsram: Within 30 minutes post-vaccination
Within 30 minutes post-vaccination
Number of Subjects With Vaccine Reactogenicity Events
Tidsram: Day 0, 1, 2, 3, 4, 5, and 6
Vaccine reactogenicity will be collected on a patient-completed diary card during checkout from Day 0 and on the next six evenings post-vaccination. The following adverse events will be solicited on the diary card: pain at injection site, tenderness at injection site, redness where the injection is given; induration/swelling (lump) where the injection is given; bruising where the injection is given; itching where the injection is given; headache; tiredness/fatigue (asthenia, lethargy, malaise); general muscle ache (myalgia); chills; nausea; vomiting. Subjects will also record their oral temperature on the diary card each evening.
Day 0, 1, 2, 3, 4, 5, and 6
Number of Subjects With Spontaneously Reported Adverse Events
Tidsram: 28 days
Subjects will be asked to report any other symptoms experienced in addition to the solicited "immediate" and "vaccine reactogenicity" events. Any other events reported will be tabulated as spontaneously reported adverse events.
28 days
Percentage of Subjects Who Received a PJ Stratis Injection Would Choose to Receive This Type of Injection Again
Tidsram: 28 Days
28 Days

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Huvudutredare: David K Cobb, MD, MPH, Rocky Mountain Infectious Disease Consultants
  • Studierektor: Linda McAllister, MD, PhD, PharmaJet, Inc.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 oktober 2012

Primärt slutförande (Faktisk)

1 mars 2013

Avslutad studie (Faktisk)

1 mars 2013

Studieregistreringsdatum

Först inskickad

17 september 2012

Först inskickad som uppfyllde QC-kriterierna

17 september 2012

Första postat (Uppskatta)

20 september 2012

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

1 november 2017

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

29 september 2017

Senast verifierad

1 september 2017

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera